The expanded partnership with Gustave Roussy, a leading cancer center in Europe, could potentially increase Sophia Genetics' market presence and revenue by providing expedited analysis and insights of genomic profiles. This could lead to increased demand for Sophia Genetics' services, potentially driving up its stock price in the short term.